298 related articles for article (PubMed ID: 33793076)
1. Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials.
Catton B; Surangiwala S; Towheed T
Int J Rheum Dis; 2021 Jul; 24(7):869-879. PubMed ID: 33793076
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
3. Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis.
Diker-Cohen T; Rosenberg D; Avni T; Shepshelovich D; Tsvetov G; Gafter-Gvili A
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 31899506
[TBL] [Abstract][Full Text] [Related]
4. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
5. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
Wu J; Zhang Q; Yan G; Jin X
J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Lyu H; Jundi B; Xu C; Tedeschi SK; Yoshida K; Zhao S; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 May; 104(5):1753-1765. PubMed ID: 30535289
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
Yuan C; Liang Y; Zhu K; Xie W
J Orthop Surg Res; 2023 Jun; 18(1):447. PubMed ID: 37349750
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
10. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
12. Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
Jiang L; Dong J; Wei J; Liu L
BMC Musculoskelet Disord; 2022 Nov; 23(1):1027. PubMed ID: 36447169
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials.
Seeto AH; Abrahamsen B; Ebeling PR; RodrÃguez AJ
J Bone Miner Res; 2021 Jan; 36(1):24-40. PubMed ID: 32780899
[TBL] [Abstract][Full Text] [Related]
14. Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.
Rosenberg D; Avni T; Tsvetov G; Gafter-Gvili A; Diker-Cohen T
Osteoporos Int; 2021 Mar; 32(3):413-424. PubMed ID: 33145606
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis.
Fontalis A; Kenanidis E; Prousali E; Potoupnis M; Tsiridis E
Expert Opin Drug Saf; 2018 Apr; 17(4):413-428. PubMed ID: 29350565
[TBL] [Abstract][Full Text] [Related]
16. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials.
Menshawy A; Mattar O; Abdulkarim A; Kasem S; Nasreldin N; Menshawy E; Mohammed S; Abdel-Maboud M; Gadelkarim M; El Ashal GG; Elgebaly AS
Support Care Cancer; 2018 Apr; 26(4):1029-1038. PubMed ID: 29387997
[TBL] [Abstract][Full Text] [Related]
17. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Li P; Wu X; Li Y; Huang J
Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.
Chandran T; Venkatachalam I
Singapore Med J; 2019 Jul; 60(7):364-378. PubMed ID: 30854568
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
Voskaridou E; Ntanasis-Stathopoulos I; Papaefstathiou A; Christoulas D; Dimopoulou M; Repa K; Papatheodorou A; Peppa M; Terpos E
Blood Adv; 2018 Nov; 2(21):2837-2847. PubMed ID: 30381400
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]